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???????
????????????????????????：To clarify the clinical characteristics of acute exacerbation of idiopathic pul­
monary fibrosis （IPF） and the involvement of infections with pathogenic microorganisms and viruses in 
acute exacerbation.
???????：During the 12 years from 2000 through 2011, we studied 50 patients who were admitted and 
received treatment for acute exacerbation of IPF in our department. Demographic characteristics, imaging 
findings, laboratory findings, changes in antibody titers against bacteria, Mycoplasma pneumoniae, Chlamy-
dophila pneumoniae, and known viruses, and outcomes were studied.
???????：Among the 50 patients with acute exacerbation of IPF （41 men and 9 women） 29 patients died 
（mortality rate, 58.0％）. Computed tomography showed subpleural peripheral ground-glass opacities （GGO） 
in 5 patients, multiple patchy GGO in 19, and diffuse GGO in 26. Only the PaO2/FiO2 ratio was significantly 
lower in the non-survivors compared with survivors. Three patients had high titers of IgM antibodies 
against C. pneumoniae, but acute infection was ruled out by the changes in IgA and IgG antibodies in paired 
serum samples. Antibody titers against known viruses significantly increased in 2 patients （respiratory syn­
cytial virus in 1 and adenovirus 11 in 1）. In acute-phase serum samples, 7 patients had increased antibody 
titers against parainfluenza virus 3, resulted in no significant change in paired serum samples.
???????????：Our results suggest that known pathogens do not play a role in acute exacerbation of IPF. 
The outcomes of IPF remain poor, and the elucidation of the causes and pathological features of acute exac­
erbation of IPF, including the identification of unknown pathogens, is awaited.
???? ????： acute exacerbation, Chlamydophila pneumoniae, idiopathic pulmonary fibrosis, Mycoplasma 
pneumoniae, viral infection
?????????????：
BAL＝bronchoalveolar lavage
CF＝complement fixation
GGO＝ground-glass opacities
HI＝hemagglutination inhibition
HRCT＝high-resolution computed tomography
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“Idiopathic pulmonary fibrosis （IPF）” is an ad­
vanced, life-threatening, interstitial lung disease of un­
known origin1,2）. In most cases, the clinical course is 
chronic and gradually progressive. The mean survival 
time has been reported to be 3 to 5 years3 ,4）. New 
shadows （infiltrates） develop in both lung fields dur­
ing the chronic phase in association with rapid disease 
progression, leading to respiratory failure. An “acute 
exacerbation of IPF” is diagnosed in the absence of 
distinct causes of disease exacerbation5）. The annual 
incidence of acute exacerbations of IPF has been re­
ported to range from 5％ to 15％6,7）. A decline in 
forced vital capacity and progressive hypoxemia are 
thought to increase the risk of acute exacerbation of 
IPF in association with disease progression8）. Whether 
such acute exacerbations of IPF directly represent fi­
brous proliferation associated with the underlying dis­
ease or are caused by other known or unknown fac­
tors remains elusive5,9）. Most acute exacerbations of 
IPF are accompanied by the presentation of symptoms 
suggesting airway infection, such as fever and cough, 
but the involvement of infection in such symptoms re­
mains unclear10,11）. Cytologic evaluation of bronchoal­
veolar lavage （BAL） fluid and histologic examination 
of lung specimens have yet to identify causative 
agents12〜15）. We therefore examined whether infec­
tions with bacteria, mycoplasma, chlamydophila, and 
known viruses are related to acute exacerbation of 
IPF.
???????
Subjects and Study Design
The study group was comprised of 50 consecutive 
patients who were admitted to the hospital because of 
acute exacerbation of IPF from January 2000 through 
December 2011. The diagnosis of IPF was established 
histologically by thoracoscopic biopsy of the lung in 4 
patients. In most of the other patients, the diagnosis 
was established on the basis of clinical findings and im­
aging studies of the chest on high-resolution computed 
tomography （HRCT）, referring to the international 
consensus statement16）. Acute exacerbation of IPF was 
diagnosed on the basis of the following criteria5,17）：a 
previous or concurrent diagnosis of IPF；aggravation 
of dyspnea within 1 month；new diffuse pulmonary in­
filtrates on chest radiography；worsening hypox­
emia；and the absence of apparent infectious agents 
and heart failure. Testing of sputum cultures, blood 
cultures, or both was performed in all patients at the 
time of acute exacerbation of IPF to rule out distinct 
bacterial infection. On admission, general blood tests, 
blood chemical tests, arterial blood gas analysis, and 
serum separation （acute-phase serum samples） were 
performed, and serum levels of KL-6 and SP-D were 
measured. After 2 to 4 weeks of treatment, serum sep­
aration （convalescent serum samples） was performed. 
Mycoplasma pneumoniae particle agglutination （PA） 
tests were conducted, and antibody titers against Chla-
mydophila pneumoniae and various viruses were mea­
sured in paired serum samples. Clinical data were ob­
tained from patient records. This study was approved 
by the Bioethics Committee of Dokkyo Medical Uni­
versity.
CT Examination
The chest HRCT protocol consisted of thin sections 
（1- to 2-mm collimation sections） obtained at 20-mm 
intervals through the chest in the supine position. Two 
observers （Y. F. and M. A.）, without knowledge of the 
patients’ clinical information, examined the chest 
HRCT scans. Ground-glass opacity was defined as an 
area of slightly increased attenuation in which the 
bronchial walls and vessels remained visible. Consoli­
dation was defined as an area of increased attenuation 
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with obscuring of the adjacent bronchial walls and ves­
sels. Honeycombing was defined as an accumulation of 
cystic spaces with thickened walls.
Sample Collection and Serology
The blood samples obtained from the subjects were 
separated by centrifugation at 3 ,000 rpm for 15 min, 
and the separated serum was stored at −80℃ until 
use. M. pneumoniae PA tests were performed, and 
IgM, IgA, and IgG antibody titers against C. pneumo-
niae were measured. Positive results of M. pneumoniae 
PA tests were defined as an antibody titer of ≥ 1：640 
times in single serum samples or a fourfold or greater 
increase in the titer in paired serum samples. IgM, 
IgA, and IgG antibody titers against C. pneumoniae 
were measured with the use of enzyme-linked immu­
nosorbent assay kits （Hitazyme C. pneumoniae, Hitachi 
Chemical Company, Ltd., Tokyo, Japan）. An index val­
ue of ≥ 1.60 was defined as positive for IgM antibod­
ies18）, and an index value of ≥ 1.10 was defined as posi­
tive for IgA or IgG antibodies19）. An increase of ≥ 1.00 
in the index value for IgA antibodies and of ≥ 1.35 for 
IgG antibodies between paired serum samples was 
considered to indicate acute infection19）. 
Antibody titers against various viruses were mea­
sured as follows：respiratory syncytial virus （RSV）, 
complement fixation （CF） test；herpes simplex virus 
（HSV）, CF；rubella virus, hemagglutination inhibition 
（HI） test；adenovirus 3 , 4 , 7 , 11 , 21 , neutralization 
（NT） test；echovirus 1, 3, 4, and 5, NT；coxsackievi­
rus A2, A3, A4, A5, and A6, NT；coxsackievirus B1, 
B2, B3, B4, B5, and B6, NT；parainfluenza virus 1, 2, 
and 3, HI；influenza virus A （H1N1） and influenza vi­
rus A （H3N2）, HI；influenza virus B1 and B2. A four­
fold or greater increase in antibody titers against vi­
ruses in paired serum samples was defined as positive. 
The procedures for the measurement of virus titers 
are described briefly below. For CF test, several virus 
antigen, and guinea-pig complement were purchased 
from Denka-Seiken Co. （Tokyo, Japan）. The virus or 
normal antigen was added to the inactivated serum, 
which was sequentially diluted by twofold. The sample 
was then incubated with complement at 4℃ overnight. 
Sensitized liposome was added to the sample and incu­
bated at 37℃ for 1 h. Release of carboxyfluorescein 
was assessed by measuring the optical density using a 
microplate reader. The maximum serum titer for nega­
tive lytic reaction was determined. For HI test, the in­
activated serum was diluted by twofold and virus anti­
gen （Denka-Seiken Co.） was mixed with the serum 
sample and incubated at room temperature for 1 h. 
Thereafter, 0.5％ chicken or guinea-pig RBC was add­
ed to the sample and incubated at room temperature 
for 1 h. Inhibition of virus-induced haemagglutination 
was observed visually and the maximum serum titer 
causing HI was determined. For NT test, the inactivat­
ed serum was diluted by twofold. Mixed with adjusted 
virus （100TCID50/25 mL） purchased from Nissui-Sei­
yaku Co. （Tokyo, Japan） and incubated at room tem­
perature for 30 min. Thereafter, the virus mixture was 
added to sensitive cell lines and cultured in Eagle 
MEM （Nissui-Seiyaku Co.） with 3％ FBS at 35℃ for 5 
days. Viral plaques were visualized by staining with 
0.1％ crystal violet in PBS containing 0.2％ formalde­
hyde and counted.
Statistical Analysis
Data are expressed as mean±SD. Comparison be­
tween survivors and nonsurvivors were performed us­
ing nonparametric methods （Mann-Whitney U-test）. 
Clinical data analysis was performed using JMP 10 .0 
（SAS Institute Inc., Cary, NC, USA）. Statistical signifi­
cance was defined as a P value less than 0.05.
???????
From January 2000 through December 2011, a total 
of 50 patients （41 men and 9 women） were admitted 
to our hospital because of acute exacerbation of IPF. 
Twenty-nine patients （58％） did not respond to inten­
sive therapy for acute exacerbation and died. Table 1 
shows the clinical characteristics of the patients. Table 
2 shows the laboratory data （on admission） and figure 
1 shows the patterns on chest HRCT in the survivors 
and non-survivors. On chest HRCT, subpleural periph­
eral dominant GGO was found in 5 patients （1 death, 
20％）, multifocal GGO in 19 （11 deaths, 58％）, and dif­
fuse GGO in 26 （19 deaths, 73％） （Table 1 , Fig. 1）. 
Many non-survivors received methylprednisolone 
pulse therapy, immunosuppressant drugs, sivelestat 
sodium hydrate, and endotracheal intubation with arti­
ficial ventilation （Table 1）. No patient received immu­
noglobulin preparations. On admission, white-cell 
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counts, C-reactive protein levels, serum lactate dehy­
drogenase levels, serum KL-6 levels, and serum sur­
factant protein D levels did not significantly differ be­
tween the survivors and non-survivors；however, the 
PaO2/FiO2 ratio was significantly lower in the non-
survivors （Table 2）. The mean interval from disease 
onset to the start of therapy was similar in the survi­
vors （7 days） and non-survivors （9 days）. 
Bacteriologic examinations on admission revealed no 
clinically significant pathogens in any patient. Conva­
lescent-phase serum samples could not be obtained 
from some patients who died during admission. Conse­
quently, paired serum samples could be evaluated in 
31 patients, including 10 non-survivors. The results of 
M. pneumoniae PA tests of acute-phase serum samples 
were negative in all patients, and there was no in­
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???????　Clinical Characteristics of Patients and Chest HRCT Patterns
Variable Survivors （n＝22） Non-survivors （n＝28）
Age, yr （range） 70 （54-82） 72 （59-87）
Gender （men/women） 17/5 24/4
Smoking （Current＋Former）, ％ 73 75
Fever （≥ 37.5℃）, ％ 66 60
Methylprednisolone pulse, ％ 45 86
Immunosuppressive drugs, ％ 32 46
Sivelestat sodium hydrate, ％ 23 50
Mechanical ventilation, ％ 5 46
HRCT pattern of GGO
Peripheral dominant 4 1
Multifocal 8 11
Diffuse 7 19
GGO denotes ground-glass opacities
????????　Representative Chest HRCT Images on Acute Exacerbation of IPF
GGO denotes ground-glass opacities.
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crease in antibody titers between paired serum sam­
ples. The C. pneumoniae IgM antibody index exceeded 
1.60 in 3 patients. However, none of these patients had 
significant increases in IgA or IgG antibody titers in 
paired serum samples. The C. pneumoniae IgA anti­
body index in acute-phase serum samples exceeded 
1.10 in 21 patients, but the index did not increase by 
≥ 1 .00 in paired serum samples in any of these pa­
tients, ruling out the possibility of acute infection. The 
C. pneumoniae IgG antibody index in acute-phase se­
rum samples exceeded 1 .10 in 24 patients. However, 
none of these patients showed an increase of ≥ 1.35 in 
paired serum samples. Acute infection was therefore 
ruled out （Fig. 2）. 
On virus antibody tests, the RSV antibody titer sig­
nificantly increased from 1：4 to 1：32 in 1 patient 
and the adenovirus 11 antibody titer significantly in­
creased from 1：4 to 1：32 in 1 patient. In acute-phase 
serum samples, antibody titers against parainfluenza 
virus 3 were elevated （ ≥ 1：320） in 7 patients, but 
none of these patients showed a significant increase in 
paired serum samples. In summary, changes in anti­
body titers against known viruses examined in this 
study did not distinctly suggest viral infection in any 
patient, with the exception of 2 patients who had a sig­
nificant increase in virus antibody titer （RSV in 1, and 
adenovirus 11 in 1） （Fig. 3）. 
??????????
A diagnosis of acute exacerbation of IPF requires 
ruling out various factors, including pneumonia, pulmo­
nary infarction, heart failure, steroid dose reduction, in­
jury caused by general anesthesia, surgery, or bron­
choscopy20,21）, and adverse effects of drugs 22）. In the 
present series of 50 patients, we ruled out potential ef­
fects of these exacerbating factors as extensively as 
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???????　Comparison of Laboratory Data on Admission Between Survivors and Non-survivors
Survivors（n＝22） Non-survivors（n＝28） P-Value
WBC （X109/l） 9.54±3.46 10.7±3.36 NS
CRP （mg/dl） 4.25±7.48 5.40±6.98 NS
LDH （U/l） 316±120 367±190 NS
KL-6 （U/ml） 1428±675 1900±1095 NS
SPD （ng/ml） 404±255 429±368 NS
PaO2/FiO2 （mmHg） 290±54.9 159±72.5 ＜0.001
Values are mean±SD.
????????　 Changes in Index Values for IgM Antibodies （a）, IgA Antibodies （b）, and IgG 
Antibodies （c） against C. pneumoniae in Acute- and Convalescent-phase 
Serum Samples （Paired Serum Samples）
In acute-phase serum samples, 3 patients had an IgM index of ≥ 1.60, but the IgA and 
IgG indexes did not satisfy the criteria for positivity. These patients were considered false 
positive. None of the 31 patients satisfied the criteria for a positive IgA or IgG index.
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possible. The mortality rate among the 50 patients 
with acute exacerbation of IPF who were treated in 
our department was 58％. The main predictor of poor 
outcomes in patients with acute exacerbation of IPF 
was a decreased PaO2/FiO2 ratio on admission （290±
54.9 mmHg in survivors vs. 159±72.5 mmHg in non-
survivors）. Consistent with the results of a study by 
Akira et al. that assessed changes on chest HRCT23）, 
the mortality rate was highest （73％） among the 26 
patients with diffuse GGO in our study.
The results of M. pneumoniae PA tests were nega­
tive in acute-phase serum samples, and there was no 
increase in antibody titers in paired serum samples in 
the 31 patients in whom these tests were performed. 
It is therefore unlikely that M. pneumoniae infection 
participated in acute exacerbation of IPF. As for C. 
pneumoniae infection, 3 patients had an IgM antibody 
index of ≥ 1 . 60 in acute-phase serum samples, but 
none of these patients significant increases in IgA or 
IgG antibody titers. They were therefore considered 
false-positive cases. Miyashita et al. reported that 16.5
％ of patients with chronic pulmonary disease and 8.6
％ of healthy subjects had a C. pneumoniae IgM anti­
body index of ≥ 1.60, which is considered positive for C. 
pneumoniae infection. However, the results of both mi­
croimmunofluorescence tests and culture tests were 
negative. Their findings suggested that false-positive 
results of C. pneumoniae IgM antibody assay occur at 
these probabilities24）. There was no significant increase 
in IgA or IgG antibody titers meeting the criteria for 
positivity in the 31 patients for whom paired serum 
samples were available. These results suggested that 
C. pneumoniae infection did not have a role in acute 
exacerbation of IPF. Tomioka et al. studied 27 patients 
with acute exacerbation of IPF to assess the role of C. 
pneumoniae infection. Among the 15 patients in whom 
antibody titers were confirmed in paired serum sam­
ples, 2 had increased titers of C. pneumoniae IgA and 
IgG antibodies. But they concluded that it was uncom­
mon for C. pneumoniae infection to participate in acute 
exacerbation of IPF25）. 
Several studies have reported acute exacerbations of 
IPF caused by viral infection, but the relation remains 
uncertain26〜28）. In one study of 43 patients, multiplex 
polymerase chain reaction （PCR） assay of BAL-fluid 
samples detected rhinovirus in 2 patients, human coro­
navirus OC43 in 1, and parainfluenza virus 1 in 129）. In 
our study, among the 31 patients in whom changes in 
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????????　 Changes in Respiratory Syncytial Virus （a）, Adenovirus 11 （b）, and Parainfluenza 
Virus 3 （c） in Acute- and Convalescent-phase Serum Samples （Paired Serum 
Samples）
（a） The antibody titer significantly increased in 1 patient （by 4 fold） （dotted line）. 
（b） The antibody titer significantly increased in 1 patient （by 4 fold） （dotted line）.
（c） Seven patients had antibody titers higher than 1：320 in acute-phase serum samples, 
but none of these patients showed a significant increase in paired serum samples.
RSV denotes Respiratory Syncytial Virus.
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antibody levels could be confirmed in paired serum 
samples, 7 showed increased parainfluenza virus 3 an­
tibody levels （ ≥ 320 fold） in acute-phase serum sam­
ples, with had no significant increase between paired 
serum samples, suggesting the risk of prior infection. 
Two patients had significant increases in antibody lev­
els （RSV in 1 and adenovirus 11 in 1）. The RSV-posi­
tive patient was a 69-year-old man who had multifocal 
GGO on chest HRCT and died 21 days after disease 
onset. The adenovirus 1 1 -positive patient was a 
7 7 -year-old man with multifocal GGO on chest 
HRCT；this patient survived. Thus, the potential in­
volvement of virus infection could not be ruled out in 
only 2 patients. Consistent with the results of Wootton 
et al., 29）infection with known viruses was not detected 
in most patients with acute exacerbation of IPF.
Our study had several important limitations. First, 
our major objective was to investigate the involvement 
of microorganisms in acute exacerbation of IPF. How­
ever, we indirectly evaluated potential involvement by 
measuring antibody titers in the sera of patients and 
did not assess microorganisms in local lung lesions. 
Second, 29 of the 50 patients died during treatment, 
and paired serum samples could not evaluated in all 
patients. The possibility remains that patients with vi­
ral infection or infection with M. pneumoniae or C. 
pneumoniae may have been included among the non-
survivors. Third, all patients received high-dose ste­
roids, and 20 received immunosuppressants. It remains 
unclear whether these drugs negatively affected the 
production of various types of antibodies. To avoid 
these problems and to identify causative microorgan­
isms in acute-phase serum samples, culture tests to 
identify pathogens in specimens of local lung lesions or 
techniques for genetic diagnosis are required. Interest­
ingly, a recent study reported that torque teno virus 
（TTV） was detected on genetic analysis in BAL fluid 
samples obtained from 12 of 43 patients with acute ex­
acerbation of IPF29）. In the present study, unfortunate­
ly, we did not evaluate TTV.
In summary, the mortality rate among 50 patients 
with acute exacerbation of IPF was 58％. The pres­
ence of diffuse GGO on chest HRCT and a decreased 
PaO2/FiO2 ratio were associated with poor outcomes. 
In 31 patients, including non-survivors, for whom 
paired serum samples were available, M. pneumoniae 
and C. pneumoniae infection was apparently unrelated 
to acute exacerbation of IPF. Two （6％） of the 31 pa­
tients had infection （RSV in 1 and adenovirus in 1）. 
However, no changes in antibody levels suggestive of 
viral infection were found in the other 29 patients. 
Therefore, infection with the known viruses studied 
apparently had a negligible role in acute exacerbation 
of IPF. Further larger studies are needed to determine 
whether infection with known TTV and other known 
viruses, unknown viruses, or other microorganisms 
contribute to acute exacerbation of IPF and to identify 
appropriate treatment for this condition, currently as­
sociated with a poor prognosis.
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